Catalyst Pharmaceuticals secures Firdapse patent protection through 2035 in Hetero settlement
Catalyst Pharmaceuticals (NASDAQ:CPRX) and its licensor, SERB, have successfully resolved their patent litigation with Hetero and its affiliates regarding Firdapse (amifampridine) 10 mg tablets.


_1395288_640x360_2499099203704-640x360.webp&w=3840&q=75)
_1395285_640x360_2499099203708-640x360.webp&w=3840&q=75)



_1395242_640x360_2499078723812-640x360.webp&w=3840&q=75)



_1395220_640x360_2499078211538-640x360.webp&w=3840&q=75)